REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

NACompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Alzheimer Disease
Interventions
BEHAVIORAL

Pleiotropic info, in-person disclosure

"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."

BEHAVIORAL

AD-only info, in-person disclosure

"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."

BEHAVIORAL

Pleiotropic info, phone disclosure

"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."

BEHAVIORAL

AD-only info, phone disclosure

"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."

Trial Locations (4)

20059

Howard University, Washington D.C.

44120

Case Western Reserve University, Cleveland

48109

University of Michigan, Ann Arbor

02118

Boston University School of Medicine, Boston

All Listed Sponsors
collaborator

National Human Genome Research Institute (NHGRI)

NIH

lead

Brigham and Women's Hospital

OTHER

NCT00462917 - REVEAL III: Risk Evaluation and Education for Alzheimer's Disease | Biotech Hunter | Biotech Hunter